Blood cancer Patients' vaccine response under the microscope

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

* INCLUSION CRITERIA: * Diagnosis of CLL, FL, MCL, MZL, NHL NOS or WM * Must fulfil one of the following criteria to be enrolled in one study arm per vaccine received: 1. Patients with CLL AND one of the following: i. Arm 1: Must be treatment naive (no prior cancer directed therapy) ii. Arm 2: Patients that have received prior cancer directed therapy and are currently not receiving active treatment iii. Arm 3: Must be receiving treatment with a BTKi. This arm is not available to patients receiving the HEPLISAV-B vaccine iv. Arm 4: Must be receiving treatment with a BTKi for \>= 6 months prior to vaccination and be willing to hold their treatment for up to 7 weeks around the time of each vaccination. This arm is not available to patients who have had a prior episode of disease flare during periods of drug hold, or for patients with CLL that is actively progressing. v. Arm 5: Must be receiving treatment with a BCL-2 inhibitor Or 2. Patients with FL, MCL, MZL, NHL NOS or WM AND one of the following: i. Arm 1: Must currently not be receiving active treatment (treatment na(SqrRoot) ve or previously treated) ii. Arm 2: Must be receiving treatment with targeted therapies (e.g. BTKi, BCL-2 inhibitors, PI3K inhibitors, immunomodulatory agents, proteasome inhibitors) * If prior exposure to Hepatitis-B vaccination, must have documentation of negative serologic response * Age \>= 18 years * Able to comprehend the investigational nature of the protocol and provide informed consent EXCLUSION CRITERIA: 1. Female patients who are currently pregnant 2. History of severe allergic reaction to vaccines 3. Concomitant inherited immunodeficiency 4. Any life-threatening illness, medical condition, or organ system dysfunction that, in the investigator s opinion, could compromise the subject s safety or put the study outcomes at undue risk. 5. Receive cytotoxic chemotherapy within 2 weeks prior to vaccination 6. Receive intravenous immunoglobulin (IVIG) within 2 months prior to vaccination 7. Receive anti-CD20 and/or anti-CD19 monoclonal antibody therapy within 6 months prior to vaccination 8. Receive cellular therapy (e.g. CAR-T cells) within 12 months prior to vaccination 9. History of allogeneic stem cell transplantation